“Medicated grass” piece touched the limit: private equity tycoons have not run, do not know that other institutions are really running

Pianzai Huang yesterday’s plunge may be related to the rumor that private equity tycoon Lin Yuan has reduced its holdings. At the end of this week, a piece of news related to Linyuan ignited the investment circle: he had two products that disappeared from the shareholders of pianzai Huang. Last Friday, the evening of October 23, Pian Zihuang released the third quarterly report. The change of shareholders disclosed that private-equity tycoon Lin Yuan “started” and has greatly reduced its holding to only 1.35 million shares. The semi annual report shows that Linyuan’s products hold 8.84 million shares. < p > < p > the forest garden famous for its “Maofen” is also a loyal fan of Pian tzihong, one of its heavy stocks. Lin Yuan also called out on many public occasions to firmly buy Pianzihuang and look at the core assets of medicine. But now he is the first to run? The investment circle will blow up. < p > < p > the reporter carefully consulted the third quarterly report of pianzi Huang and found that Linyuan investment No.21 private investment fund and No.101 private securities investment fund of Linyuan investment have all withdrawn from the list of top ten shareholders. Although the No. 29 private investment fund of Linyuan investment was still in existence, it also reduced its holding of 1188500 shares. < / P > < p > the investment trend of private equity tycoons has always been concerned by the market. Lin Yuan, chairman of the board of directors of Linyuan investment, also publicly responded to the question that “the forest park has run away”. Lin Yuan, the chairman of the board of directors of Linyuan investment, also publicly responded to the question yesterday. Instead of reducing the positions of some funds with a scale of more than 10-2 billion yuan, Lin Yuan just split up four or five times. Although the financial report shows that some products are no longer listed in the top ten circulating shareholders, the actual shares have not changed. < / P > < p > whether investors believe it or not, we can’t find the position of Linyuan from the open channel. This situation is similar to the situation of Maotai shares held by Linyuan. It is said that the shares were hidden after dispersed positions. It is still uncertain whether Linyuan will run or not, but some other institutions have. Hong Kong Central Clearing Co., Ltd. (Note: the agent company of foreign investors) and GF Shuangqing upgraded hybrid securities investment fund are also reducing their holdings, with 1.93 million shares and 1.5 million shares respectively. At the same time, the number of shareholders in Pian tzihu has increased significantly. The reporter noted that as of September 30, the number of shareholders was 110237. Compared with 72440 shareholders as of June 30 disclosed in the semi annual report, the number increased by 52.18%. This also means that some institutions and private placement may have successfully shipped and exchanged chips to retail investors. In recent six years, its stock price has soared 10 times, and since this year it has more than doubled. It is an absolute pharmaceutical Bull Stock. From January to September this year, the company achieved 5.070 billion yuan of operating revenue, a year-on-year increase of 16.78%, and a net profit of 1.329 billion yuan, a year-on-year increase of 19.83%. However, the growth rate of net profit was lower than that of the same period of last year. However, pianzai Huang also issued an announcement saying that it plans to start the preparatory work for the listing of Fujian pianzheng Cosmetics Co., Ltd., a subsidiary of the company. Established in 2002, the company is mainly engaged in the R & D, production and sales of cosmetics, with brands such as “Pianzihuang” and “Queen”, and its products cover skin care products, cleaning and care series. < p > < p > after years of development, Pianzihuang cosmetics have a certain reputation and are recognized by the market. From 2017 to 2019 and the first half of 2020, the revenue of Pianzihuang cosmetics was 175 million yuan, 274 million yuan, 430 million yuan and 330 million yuan respectively; the net profit was 21.03 million yuan, 42.49 million yuan, 80.94 million yuan and 74.22 million yuan respectively. < p > < p > from the revenue point of view, Pianzihuang mainly relies on the pharmaceutical business, and the cosmetics business only accounts for about 10% of the total revenue. But the cosmetics business is the second highest gross profit product after pharmaceuticals. In the first half of 2020, the gross profit rate of the drugs used for Pianzihuang liver disease was 79.49%, while that of cosmetics and daily chemicals was 64.09%. < / P > < p > it is worth mentioning that from the third quarter report, the reporter found that the gross profit rate of liver disease medication of the core product of Pianzihuang decreased by 1.74 percentage points year-on-year. At the beginning of this year, pianzai Huang also raised the retail price of its core products, raising the domestic retail price of Pianzihuang tablet from 530 yuan / tablet to 590 yuan / tablet, and the supply price increased by about 40 yuan / tablet; and the supply price in overseas market increased by about 5.80 US dollars / tablet.

it is often seen. In recent years, pharmaceutical companies have been doing cosmetic and cosmetic operations. Most familiar products are toothpaste produced by Baiyao, Tongrentang production mask, and Yunnan’s eye cream. From the present point of view, Pianzihuang is also the first pharmaceutical company to spin off the cosmetics business. < p > < p > the purpose of this article reprinted by China net finance and economics is to convey more information, which does not represent the views and positions of the website. The content of this paper is for reference only and does not constitute investment advice. Investors operate accordingly and bear their own risks.